Results 21 to 30 of about 28,207 (244)
ESC Heart Failure, 2021 Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni +9 more
doaj +1 more source
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen significant advances in disease-modifying therapies, increased awareness of CA, and improved
Lily K. Stern, Jignesh Patel
openaire +3 more sources
Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis
Methodist DeBakey Cardiovascular Journal, 2022 Cardiac amyloidosis is increasingly recognized as an underlying cause of left ventricular wall thickening, heart failure, and arrhythmia with variable clinical presentation.
Sajan S. Gill +4 more
doaj +1 more source
JACC. CardioOncology, 2020 Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD +8 more
doaj +1 more source
PLoS ONE, 2022 BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy +11 more
doaj +1 more source
Cardiac Amyloidosis and Endomyocardial Biopsy: Correlation of Extent and pattern of Deposition with Amyloid Immunophenotype by immunogold in a single institution [PDF]
, 2023 openBackground: Amyloidosis is an infiltrative systemic disease characterized by the extracellular deposition of fibrillar proteins in different organs leading to tissue damage and dysfunction. Cardiac involvement by amyloidosis is common.
DI MIRA, COSIMO JUNIOR
core
Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis
Radiology Case Reports, 2018 Cardiac amyloidosis is an under-appreciated cause of heart failure. Establishing a diagnosis is important because traditional heart failure treatment regimens can worsen left ventricular failure in this disease. Endomyocardial biopsy is the gold standard
Martin Krupa, MD +3 more
doaj +1 more source
SAGE Open Medical Case Reports, 2020 Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe +5 more
doaj +1 more source
Nuclear imaging for cardiac amyloidosis [PDF]
, 2015 Histological analysis of endomyocardial tissue is still the gold standard for the diagnosis of cardiac amyloidosis, but has its limitations. Accordingly, there is a need for non-invasive modalities to diagnose cardiac amyloidosis.
Longhi, Simone +8 more
core +2 more sources
ESC Heart Failure, 2021 Aims As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%.
Ana Devesa +10 more
doaj +1 more source